Introduction Vaccination with Vi capsular polysaccharide (Vi-PS) or protein-Vi typhoid
conjugate vaccine (TCV) can protect adults against Salmonella Typhi infections. TCVs offer …

Vaccine development to prevent Salmonella Typhi infections has accelerated over the past
decade, resulting in licensure of new vaccines, which use the Vi polysaccharide (Vi PS) of …

Vaccination against Salmonella Typhi using the Vi capsular polysaccharide, a T-cell
independent antigen, can protect from the development of typhoid fever. This implies that …

Vi-polysaccharide conjugate vaccines are efficacious against cases of typhoid fever;
however, an absolute correlate of protection is not established. In this study, we investigated …

Typhoid fever is a public health problem, especially among young children in developing
countries. To address this need, a glycoconjugate vaccine Vi-CRM197, composed of the …

In recent years there have been major efforts to develop glycoconjugate vaccines based on
the Vi polysaccharide that will protect against Salmonella enterica Typhi infections …

Salmonella Typhi is the causative agent of typhoid fever in humans, responsible for
approximately 21 million infections and 222,000 deaths globally each year. The current …

Background The capsular polysaccharide of Salmonella enterica serovar Typhi, Vi antigen,
is an essential virulence factor and a protective antigen. Similar to other polysaccharide …

Typhoid Vi vaccines have been shown to be efficacious in children living in endemic
regions; however, a widely accepted correlate of protection remains to be established. We …

Vi capsular polysaccharide (Vi) conjugate vaccines, which can prevent typhoid in infants
and young children, are being developed. Comparative immunogenicity studies are …